Dynamics of Adaptive Immune Cell and NK Cell Subsets in Patients With Ankylosing Spondylitis After IL-17A Inhibition by Secukinumab
Background: Anti-IL-17A therapy is generally effectively applied in patients with Ankylosing Spondylitis (AS) to achieve and maintain remission. However, the influence of anti-IL-17A on the composition of the immune system is not apparent. Our prospective study was to explore the changes in immune i...
Saved in:
Main Authors: | Yutong Jiang (Author), Mingcan Yang (Author), Yanli Zhang (Author), Yefei Huang (Author), Jialing Wu (Author), Ya Xie (Author), Qiujing Wei (Author), Zetao Liao (Author), Jieruo Gu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
by: Liudan Tu, et al.
Published: (2020) -
Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative Study
by: Jialing Wu, et al.
Published: (2020) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016) -
Effectiveness of secukinumab for overlapping hidradenitis suppurativa and ankylosing spondylitis
by: Mariam AlAfeefi, et al.
Published: (2024) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021)